Abstract
The TP53 mutations have been proved to be predominated in ovarian cancer in a study from The Cancer Genome Atlas (TCGA). However, the molecular characteristics of recurrent ovarian cancers following initial treatment have been poorly estimated. This study was to investigate the pattern of somatic point mutations in matched paired samples of primary and recurrent epithelial ovarian cancers, using the OncoMap mutation detection protocol. We have adapted a high-throughput genotyping platform to determine the mutation status of a large panel of known cancer genes. OncoMap v.4.4 was used to evaluate genomic DNA isolated from a set of 92 formalin-fixed, paraffin-embedded (FFPE) tumors, consisting of matched paired samples of initially diagnosed and recurrent tumors from 46 epithelial ovarian cancer (EOC) patients. Mutations were observed in 33.7% of the samples, with 29.3% of these samples having a single mutation and the remaining 4.3% having two or more mutations. Among the 41 genes analyzed, 35 mutations were found in four genes, namely, CDKN2A (2.2%), KRAS (6.5%), MLH1 (8.2%) and TP53 (20.7%). TP53 was the most frequently mutated gene, but there was no correlation between the presence of mutation in any gene and clinical prognosis. Furthermore, somatic mutations did not differ between primary and recurrent ovarian carcinomas. Every mutation present in recurrent samples was detected in the corresponding primary sample. In conclusion, these OncoMap data of Korean EOC samples provide that somatic mutations were found in CDKN2A, KRAS, MLH1, and TP53. No differences in mutational status between primary and recurrent samples were detected. To understand the biology of tumor recurrence in epithelial ovarian cancer, more studies are necessary, including epigenetic modifications or additional mutations in other genes.
Highlights
Ovarian cancer is the most common cause of death among the gynecologic malignancies [1]
TP53 mutations and MLH1 mutations appeared in papillary serous adenocarcinoma, and otherwise KRAS mutations and cyclin-dependent kinase inhibitor 2A (CDKN2A) mutations showed up mainly in mucinous adenocarcinoma (Table 3)
The OncoMap platform can be used to analyze DNA derived from both fresh-frozen tissue and FFPE specimens
Summary
Ovarian cancer is the most common cause of death among the gynecologic malignancies [1]. The standard treatment is surgical cytoreduction followed by platinum-based chemotherapy. Most patients eventually relapse and die of chemo-resistant disease. Available salvage regimens for platinumrefractory ovarian cancer have yielded disappointing results, because response rates are low (20–50%) and the responses are short in duration. It is necessary to examine new treatment strategies for both newly diagnosed patients as well as patients with recurrent cancer [2]. New means of molecularly and genetically characterizing ovarian cancer are needed in order to personalize and improve treatment [3]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have